Program

Program Overview and Highlights

Please note that each program title and detail is subject to be updated or changed later.

At JSMO 2024, more than 70% of the presentations were conducted in English, including about 40% of the Keynote Sessions and 80+% of the Oral & Poster Sessions. JSMO 2025 will also welcome participants with many cutting-edge abstracts from Asia and around the world.

The JSMO 2025 program will include:

• A special lecture by Dr. Hisataka Kobayashi from the National Cancer Institute in the USA
• A special lecture by Prof. Ajay Goel from Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope
• A Presidential Symposium featuring the latest topics, including whole genome analysis, liquid biopsy, and artificial intelligence in cancer therapy
• Joint symposiums with ASCO, ESMO, the Asian Pacific Society, and SIOG
• Multiple symposiums highlighting various cancer fields
• Daily rapid oral abstract sessions featuring brief presentations on the most relevant research topics
• Daily poster sessions

• Special Lecture
• Special Session
• Presidential Symposium
• Symposium
• Joint Symposium with International Societies
• Joint Symposium with Japanese Societies
• Educational Lecture

Special Lecture

Special Session

Session Information

Chair	Hironobu Minami	(Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University, JP)
Speaker	Hironobu Minami	(Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University, JP)
	Issei Komuro	(International University of Health and Welfare, JP)

Presidential Symposium

Session Information

Chair	Yasushi Sato	(Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences, JP)
	François-Clément Bidard	(Institut Curie, FRA)
Speaker	Yoshiaki Nakamura	(National Cancer Center Hospital East, JP)
	Jeanne Tie	(Peter MacCallum Cancer Centre, Walter & Eliza Hall Institute of Medical Research, AUS)
	François-Clément Bidard	(Institut Curie, FRA)
	Eiji Iwama	(Department of Respiratory Medicine, JP)
	Shusuke Akamatsu	(Department of Urology, Nagoya University Graduate School of Medicine, JP)

Session Information

Chair	Manabu Muto	(Department of Medical Oncology, Kyoto University Graduate School of Medicine, JP)
	Oda Katsutoshi	(Division of Integrative Genomics, The University of Tokyo, JP)
Keynote Lecture
	Sasdakatsu Ikeda	(Department of Precision Cancer Medicine, Institute of Science Tokyo, JP)
Speaker	Tatsuya Suzuki	(National Cancer Center, JP)
	Junko Takita	(Department of Pediatrics, Graduate School of Medicine, Kyoto University, JP)
	Shinsuke Amano	(Japan Federation of Cancer Patient Groups, JP)
	Takashi Oshio	(Hitotsubashi University, Institute of Economic Research, JP)

Session Information

In 2025, whole genome sequencing will be introduced into clinical practice based on the Whole Genome Analysis 2022 Action Plan. We will hear about the current situation in the Netherlands, where clinical implementation has already been realized, and discuss the clinical usefulness of whole genome sequencing.

Chair	Takashi Kohno	(National Cancer Center Research Institute, JP)
Speaker	Takashi Kohno	(National Cancer Center Research Institute, JP)
	Kuniko Sunami	(Department of Laboratory Medicine, National Cancer Center Hospital, JP)
	Motohiro Kato	(Department of Pediatrics, the University of Tokyo, JP)
	Tatsuhiro Shibata	(The Institute of Medical Science, The University of Tokyo, JP)

Session Information

With the promotion of genomic medicine, the existence of familial tumors is now considered more important than ever. In rare cancers, familial tumors are even more important than other carcinomas, and this is why we have included them in this symposium.

Chair	Akihiro Sakurai	(Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, JP)
	Makoto Hirata	(Department of Genetic Medicine and Services, National Cancer Center Hospital, JP)
Speaker	Masahiko Tanabe	(The University of Tokyo Hospital, The Department of Breast and Endocrine Surgery, JP)
	Eijiro Nakamura	(Department of Urology at National Cancer Center Hospital Japan, JP)
	Yoshiaki Kubo	(Department of Dermatology, Tokushima University Graduate School of Medical Science, JP)
	Hiroyoshi Hattori	(National Hospital Organization Nagoya Medical Center, Department of Clinical Genetics, JP)
	Takeshi Nakajima	(Osaka International Cancer Institute, Department of Genetic Oncology (Hereditary Tumors), JP)

Session Information

Chair	Takayuki Yoshino	(National Cancer Center Hospital East, JP)
	Kei Muro	(Department of Clinical Oncology, Aichi Cancer Center Hospital, JP)
Speaker	John H. Strickler	(Duke University, USA)
	Hisato Kawakami	(Department of Medical Oncology, Kindai University Faculty of Medicine, JP)
	Tae-Won Kim	(Asan Medical Center, KOR)
	Taroh Satoh	(Center for Cancer Genomics and Precision Medicine, Osaka University Hospital, JP)
	Kopetz Scott	(MD Anderson Cancer Center, USA)

Session Information

Chair	Eishi Baba	(Department of Comprehensive Oncology, Kyushu University, JP)
	Manabu Muto	(Kyoto University Graduate School of Medicine, Department of Medical Oncology, JP)
Speaker	Takaaki Mizuno	(Genomics Unit, Keio Cancer Center, Keio University School of Medicine, JP)
	Junichi Matsubara	(Department of Medical Oncology, Kyoto University Graduate School of Medicine, JP)
	Ippei Fukada	(Genomic Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, JP)
	Hiroshi Kitamura	(Department of Urology, Faculty of Medicine, University of Toyama, JP)

Symposium

Gastrointestinal Oncology

Session Information

In addition to conventional cancer treatments such as surgery, radiation, and chemotherapy, immunotherapy has become an established treatment strategy. Furthermore, the options for immunotherapy and molecular targeted therapy have become more diversified. Additionally, the development of new diagnostic methods using ctDNA and others is indispensable for the advancement of treatment. By making use of these approaching, these approaches, treatment strategies aimed at achieving long-term survival, cure, and organ preservation are being attempted. In this session, experts will discuss the future perspectives from thier own positions.

Chair	Izuma Nakayama	(National Cancer Center Hospital East, Gastrointestinal Oncology, JP)
	Elizabeth Smith	(Oxford Cancer, GBR)
Keynote Lecture
	Izuma Nakayama	(National Cancer Center Hospital East, Gastrointestinal Oncology, JP)
	Filippo Pietrantonio	(Fondazione IRCCS Istituto Nazionale dei Tumori, ITA)
Discussant
	Filippo Pietrantonio	(Fondazione IRCCS Istituto Nazionale dei Tumori, ITA)
	Yukihide Kanemitsu	(Department of Colorectal Surgery, National Cancer Center, JP)
	Yoshiaki Nakamura	(National Cancer Center Hospital East, JP)
	Hiroki Osumi	(Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, JP)
	Itaru Yasufuku	(Department of Clinical Anatomy Development Studies, Gifu University Graduate School of Medicine, JP)

Session Information

Share findings and discuss future perspectives on emarging therapies for upper GI cancers

Chair	Daisuke Takahari	(Department of Medical Oncology, Gunma University Graduate School of Medicine, JP)
	Hanneke W.M. van Laarhoven	(Amsterdam UMC, Dept of Medical Oncology, NLD)
Speaker	Sylvie Lorenzen	(Klinikum rechts der Isar, technical University Munich, Germany, DEU)
	Hanneke W.M. van Laarhoven	(Amsterdam UMC, Dept of Medical Oncology, NLD)
	Ian Chau	(Royal Marsden Hospital, GBR)
	Yukiya Narita	(Department of Clinical Oncology, JP)
	Shigehiro Koganemaru	(National Cancer Center Hospital East　Department of Experimental Therapeutics, JP)

Hepatobiliary and Pancreatic Oncology

Session Information

To review current treatment strategies for the perioperative management of resectable and borderline resectable pancreatic cancer in different countries and explore future perspectives in this field.

Chair	Masato Ozaka	(Cancer Institute Hospital, Japanese Foundation for Cancer Research, JP)
	Li-Tzong Chen	(Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University; National Intsitute of Cancer Research, National Health Research Institutes, Tainan, TWN)
Panelist	Teresa Macarulla	(Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, ESP)
	Li-Tzong Chen	(Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University; National Intsitute of Cancer Research, National Health Research Institutes, Tainan, TWN)
	Do-Youn Oh	(Seoul National University Hospital, KOR)
	Shuichi Aoki	(Department of Surgery, Tohoku University Graduate School of Medicine, JP)

Session Information

The discussion will focus on how GC+S-1 developed in Japan can be positioned compared to the global standard GC plus immune checkpoint inhibitor.

Chair	Makoto Ueno	(Department of Gastroenterology, Kanagawa Cancer Center, JP)
	Do-Youn Oh	(Seoul National University Hospital, KOR)
Speaker (Pro)
	Chigusa Morizane	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, JP)
Speaker (Con)
	Tatsuya Ioka	(Department of Oncology Center, Yamaguchi University Hospital, JP)
	Etsuro Hatano	(Department of Surgery, Kyoto University, JP)
Oversight by the Chair

Thoracic Oncology

Session Information

Leading experts from both domestic and international arenas, who are active at the forefront of their fields, come together to discuss the latest technologies and findings in the realm of lung cancer. Physicians involved in clinical development from around the world will present on the latest advancements in ADC/Bi-specific Antibody, the evolution of T cell engager technology, and an overview and potential of TTField Therapy. In addition, the current state of developments in pathological diagnosis through AI and radiological image diagnosis will be introduced, and the challenges ahead will be discussed.

Chair	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University, Faculty of Medicine, JP)
	Takehito Shukuya	(Department of Respiratory Medicine, JP)
Speaker	Byoung Chul Cho	(Yonsei Cancer Center, Yonsei University College of Medicine, KOR)
	Tatsuya Yoshida	(National Cancer Center Hospital, Department of Thoracic Oncology, JP)
	Ticiana Leal	(Emory University, USA)
	Takuo Hayashi	(Department of Human Pathology, Juntendo University School of Medicine, JP)
	Yoshiharu Ohno	(Department of Diagnostic Radiology, Fujita Health University School of Medicine, JP)

Session Information

The prognosis in lung cancer patients has dramatically improved with the clinical introduction of genomic medicine and immunotherapy such as ICI. On the other hand, such therapies have already reached their limits, and new breakthrough therapy are needed. In this symposium, we will discuss the current status of genomic medicine, which contributes significantly to the therapeutic outcome of lung cancer, and the future direction of therapeutic development.

Chair	Satoshi Oizumi	(Department of Respiratory Medicine, NHO Hokkaido Cancer Center, JP)
	Toshiyuki Kozuki	(National Hospital Organization Shikoku Cancer Center, JP)
Speaker	Solange Peters	(Lausanne University Hospital, CHE)
	Junko Tanizaki	(Department of Medical Oncology, Kindai University Faculty of Medicine, JP)
	Hiroki Izumi	(Department of Thoracic Oncology, National Cancer Center Hospital East, JP)
	Daniel SW Tan	(National Cancer Centre Singapore, SGP)
	Shun Lu	(Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, CHN)

Hematology Oncology

Session Information

Immunotherapies against malignant lymphoma (ML) and multiple myeloma (MM) have significantly improved prognosis in patients with ML and MM. Development of CAR-T cell therapies as well as bispecifi antibodies has drawn attention to further improve their outcomes. To select the best choice of anti-ML and -MM therapies, we need to deeply understatnd the current state of immunotherapies in Japan and also novel modalies of CAR-T and bispecific antibodies.

Chair	Kentaro Fukushima	(Department of Hematology and Oncology, Osaka University Graduate School of Medicine, JP)
	Wee-Joo Chng	(National University of Singapore, SGP)
Speaker	Grzegorz Stanislaw Nowakowski	(Mayo Clinic, USA)
	Shinichi Makita	(Department of Hematology, National Cancer Center Hospital, Tokyo, Japan, JP)
	Kentaro Fukushima	(Department of Hematology and Oncology, Osaka University Graduate School of Medicine, JP)
	Takeshi Harada	(Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, JP)

Session Information

International session regarding the cutting edge of genomic medicine and novel therapy in hematologic malignancies (malignant lymphoma and leukemia)

Chair	Kennosuke Karube	(Department of Pathology and Laboratory Medicine, JP)
	Yosuke Minami	(Department of Hematology, National Cancer Center Hospital East, JP)
Speaker	Kennosuke Karube	(Department of Pathology and Laboratory Medicine, JP)
	Nathan Fowler	(BostonGene, USA)
	Yosuke Minami	(Department of Hematology, National Cancer Center Hospital East, JP)
	Jorge E Cortes	(Georgia Cancer Center, USA)

Breast cancer

Symposium
Not too little, not too much：Optimizing more vs. less treatment for older patients with breast cancer

Session Information

De-staging may be a better option for older patients with curable early-stage breast cancer, taking into account their general condition. Collaborative decision making, which aims to facilitate decision making in line with patient values, can guide health care providers and patients in complex decisions to optimize breast cancer treatment. This session will discuss optimal surgery, radiation, drugs, and risk assessment for breast cancer in the elderly, taking into account risk-benefit considerations.

Chair	Hiroshi Ishiguro	(Saitama Medical University International Medical Center, JP)
Keynote Lecture
	Etienne Brain	(Institut Curie, FRA)
Panelist	Yasuaki Sagara	(Department of Breast and Thyroid Surgical Oncology, JP)
	Akihiko Shimomura	(National Center for Global Health and Medicine, JP)
	Yuichiro Kikawa	(Kansai Medical University, Department of Breast Surgery, JP)

Session Information

Antibody-drug conjugates (ADCs) have revolutionized the practice of metastatic and recurrent breast cancer. HER2 and Trop2 are now available as target molecules, and ADCs for various targets such as HER3 and B7H4 will emerge in the future. On the other hand, the increase in treatment options has raised new issues. Specifically, what is the optimal therapy, what is the optimal sequencing and combination therapy, and appropriate adverse event management. More than ever, management considerations must be based on clinical trial data and real-world data on drugs. In this session, four experts will discuss the latest ADCs, combination therapy, sequencing, adverse event management, and resistance mechanisms and how to overcome them, sharing with us the profound world of cutting-edge ADC development for breast cancer.

Chair	Junji Tsurutani	(Advanced Cancer Translational Research Institute, JP)
	Shanu Modi	(Memorial Sloan Kettering Cancer Center, USA)
Panelist	Ayumi Saito	(National Cancer Center Hospital, The Department of Medical Oncology, JP)
	Paolo Tarantino	(Dana-Farber Cancer Institute, USA)
	Aleix Prat	(Hospital Clinic Barcelona, FRCB-IDIBAPS, ESP)

Gynecologic Oncology

Symposium
New drug treatments for gynecological cancers

Session Information

Chair	Kan Yonemori	(National Cancer Center Hosptial, Japan, JP)
	Jae-Weon Kim	(Seoul National University, KOR)
Speaker	Shannon N Westin	(University of Texas MD Anderson Cancer Center, USA)
	Kathleen N Moore	(Stephenson Cancer Center at OU Health, USA)

Urological Oncology

Session Information

1st line treatment strategy for mRCC is still controversial. Long followup results of IO combination regimens revealed some problems; limited efficacy of IO combination regimen for primary site, low efficacy of IO combination regimens in favorable risk patients, and worsened HR of OS in IO-TKI regimens, showing the need of further breakthrough for better survival of mRCC patients. In this program, latest topics of 1st line treatment for mRCC will be presented, especially focusing on HIF-2α inhibitor as a next promising drug for mRCC.

Chair	Thomas Powles	(Centre for Experimental Cancer Medicine, Barts Cancer Institute, GBR)
	Masayuki Takahashi	(Department of Urology, Tokushima University Graduate School of Biomedical Sciences, JP)
Speaker	Ken-ichi Tabata	(Department of Urology, Kitasato University Kitasato Insititute Hospital, JP)
	Ravindran Kanesvaran	(Division of Medical Oncology, National Cancer Centre Singapore, SGP)
	Kohji Takemura	(Toranomon Hospital Department of Medical Oncology, JP)
	Eric Jonasch	(UT MD Anderson Cancer Center, USA)
Oversight by the Chair
	Thomas Powles	(Centre for Experimental Cancer Medicine, Barts Cancer Institute, GBR)

Head and Neck Cancer

Session Information

Drug therapy for thyroid cancer has mainly used sorafenib and lenvatinib, which are multi-kinase inhibitors, but serpercatinib, which targets RET mutations and fusion genes, has been added. In addition, development of therapies for BRAF gene mutations is underway, which is expected to lead to major advances in personalized medicine.
We will learn and discuss the latest information from Japan and abroad on treatment strategies for thyroid cancer, which is becoming more complex with increasing treatment options, and the future prospects for personalized medicine.

Chair	Tomoya Yokota	(Division of Gastrointestinal Oncology, Shizuoka Cancer Center, JP)
	Hisham Mehanna	(InHANSE, College of Medicine and Health, University of Birmingham, GBR)
Speaker	Bhumsuk Keam	(Seoul National University Hospital, KOR)
	Naoki Fukuda	(Department of Medical Oncology, The Cancer Institute Hospital of JFCR, JP)
	Tomohiro Enokida	(National Cancer Center, Department of Head and Neck Medical Oncology, JP)
	Ken-ichi Ito	(Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, JP)

Rare Cancer

Session Information

Treatment strategies for rare cancers, as with other types of cancer, are moving in the direction of personalized medicine. In this context, we will discuss promising drugs that will soon be available for use in practical practice for each cancer types of rare cancers.

Chair	Takafumi Koyama	(Department of Experimental Therapeutics, National Cancer Center Hospital, JP)
	Akihiro Nishiyama	(Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan, JP)
Speaker	Tatsunori Shimoi	(Department of Medical Oncology, National Cancer Center Hospital, JP)
	Toshihiko Doi	(National Cancer Center Hospital East, JP)
	Toshiki Masuishi	(Department of Clinical Oncology, Aichi Cancer Center Hospital, JP)
	Akira Kawai	(Department of Musculoskeletal Oncology and Rehabilitation Medicine, JP)
	Kazuhiko Kurozumi	(Department of Neurosurgery, Hamamatsu University School of Medicine, JP)

Translational Research/Clinical Pharmacology

Session Information

Advanced cancer drug therapy has made remarkable progress with the discovery of various driver oncogenes and the development of their inhibitors. However, disease progression due to resistance remains a significant challenge, and translational research aimed at overcoming this problem will continue to be crucial in the future. In this symposium, both basic and translational researchers will present their latest findings and discuss the remaining issues for further enhancing cancer treatment in the future.

Chair	Tadaaki Yamada	(Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, JP)
	Ryohei Katayama	(Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, JP)
Speaker	Ryohei Katayama	(Div of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, JP)
	Kenichi Suda	(Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, JP)
	Shingo Matsumoto	(Department of Thoracic Oncology, National Cancer Center Hospital East, JP)
	Eiji Iwama	(Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, JP)

Session Information

Cancer immunotherapy has entered the era of combined immunotherapy from that of single-agent immunotherapy, and various combination therapies have been introduced, but some of them are used with few basic rationales. In this symposium, we will review the basic backgrounds and discuss how combination therapies are used in clinical practice, especially in lung cancer, which can help us to select the best partner for combination therapies.

Chair	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, JP)
	Yasushi goto	(Thoracic Oncology, National Cancer Center Hospital, JP)
Speaker	Yosuke Togashi	(Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, JP)
	Kiichiro Ninomiya	(Center for Comprehensive Genomic Medicine, Okayama University Hospital, JP)
	Hidetoshi Hayashi	(Department of Medical Oncology, Kindai University, Faculty of Medicine, JP)
	Satoru Miura	(Niigata Cancer Center Hospital, JP)
	Yasushi goto	(Thoracic Oncology, National Cancer Center Hospital, JP)

Session Information

When molecular pathology targets are used, molecular pathology diagnosis by pathologists is required as a companion diagnosis for immunohistochemical staining and/or FISH. In this symosium, we will have some presentations on various molecular pathology diagnoses for various cancer types, which can be useful for the collaboration between clinicians and pathologists.

Chair	Yasushi Yatabe	(National Cancer Center Hospital, JP)
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, JP)
Speaker	Yasushi Yatabe	(National Cancer Center Hospital, JP)
	Masayuki Yoshida	(Department of Diagnostic Pathology, JP)
	Satoshi Fujii	(Department of Molecular Pathology, Yokohama City University Graduate School of Medicine, JP)
	Toshitaka Nagao	(Department of Anatomic Pathology, Tokyo Medical University, JP)

Palliative Care/Symptom Management

Session Information

Chair	Kazuhiro Yanagihara	(Department of Medical Oncology, Kansai Electric Power Hospital, JP)
	Inui Tomohiro	(Tokusima University hospital　Cancer management center, JP)
Speaker	Akiko Hanai	(Chiba University Faculity of Informatics, JP)
	Yoichiro Yoshida	(Center for Medical Informatics and Data Science, Fukuoka University Hospital, JP)
	Hiroto Ishiki	(Department of Palliative Medicine, National Cancer Center Hospital, JP)
	Emi Kubo	(National Cancer Center Hospital East, JP)
	Toshiari Kawai	(The Cancer Institute Hospital of JFCR Department of Psycho-Oncology, JP)

Session Information

Chair	Eriko Satomi	(Department of Palliative Medicine, National Cancer Center Hospital, JP)
	Akira Inoue	(Department of Palliative Medicine, Tohoku University School of Medicine, JP)
Speaker	Yoshihisa Matsumoto	(Department of Palliative Therapy, JP)
	Takeo Takahashi	(Department of Radiation Oncology, Saitama Medical Center, Saitama Medical University, JP)
	Miyuki Sone	(Department of Diagnostic Radiology/Interventional Radiology Center, National Cancer Center Hospital, JP)
	Keita Tagami	(Yushoukai Life Care Clinic Nerima, JP)

Session Information

Chair	Asao Ogawa	(Department of Psycho-Oncology Service, National Cancer Center Hospital East, JP)
	Ayako Mori	(Nursing department, National Cancer Center Hospital, JP)
Chair’s Presentation
	Asao Ogawa	(Department of Psycho-Oncology Service, National Cancer Center Hospital East, JP)
Speaker	Masakazu Abe	(Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, JP)
	Takeshi Yoshida	(Palliative Care Center and Department of Medical Oncology, Kindai University Hospital, JP)
	Hideaki Hasuo	(Department of Psychosomatic Medicine, Kansai Medcial University, JP)
	Rieko Shimizu	(Center for Physician Referral and Medical Social Service, National Cancer Center Hosptal, JP)

Cross-sectional Program

Session Information

Chair	Yasutoshi Kuboki	(Department of Experimental Therapeutics, National Cancer Center Hospital East, JP)
	Toshio Shimizu	(Department of New Experimental Therapeutics, International Cancer New Drug Development Center, Kansai Medical University Hospital, JP / NEXT Oncology KMU JAPAN/NEXT Oncology, TX USA)
Speaker	Shigehisa Kitano	(Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, JP)
	Megumi Ishiguro	(Health Science Research & Development Center (HeRD), Institute of Science Tokyo, JP)
	Takako Nakajima	(Kyoto University Graduate School of Medicine, Department of Early Clinical Development, JP)
	Noboru Yamamoto	(National Cancer Center Hospital, JP)

Session Information

Chair	Maki Tanioka	(Okayama University, Medical AI project, JP)
	Kenji Hirata	(Department of Diagnostic Imaging, Faculty of Medicine, Hokkaido University, JP)
Speaker	Gen Tamiya	(Department of AI and Innovative Medicine, Tohoku University Graduate School of Medicine/Statistical Genetics Team, RIKEN Center for Advanced Intelligence Project, JP)
	Maki Tanioka	(Okayama University, Medical AI project, JP)
	Ishikawa Shumpei	(Department of Preventive Medicine, Graduate School of Medicine, The University of Tokyo / Division of Pathology, Exploratory Oncology Research & Clinical Trial Center Pathology, National Cancer Center, JP)
	Hamamoto Ryuji	(Division of Medical AI Research and Development, National Cancer Center Research Institute, JP)
	Ken’ichi Morooka	(Faculty of Advanced Science and Technology, Kumamoto University, JP)

Session Information

Chair	Kenji Tamura	(Department of Medical Oncology, Shimane University Hospital, JP)
	Ryuji Hayashi	(Toyama University Hospital, Clinical Oncology, JP)
Speaker	Yuji Miura	(Department of Medical Oncology, Toranomon Hospital, JP)
	Shingo Yano	(Division of Clinical Oncology and Hematology, The Jikei University School of Medicine, JP)
	Fumikata Hara	(Department of Breast Oncology, Aichi Cancer Center, JP)
	Rinpei Niwa	(Research Division, Kyowa Kirin, JP)

Multidisciplinary Team Program

Session Information

Chair	Tetsuhiro Yoshinami	(Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital, JP)
	Chie Watanabe	(Showa University School of Nursing & Rehabilitation Sciences, JP)
Keynote Lecture
	Hiroyuki Shibata	(Dept. Clinical Oncol. Akita Univ., JP)
Speaker	Tatsuya Takagi	(Juntendo Univ. Palliative Medicine, Orthopedics, Rehabilitation Medicine, JP)
	Hisayasu Nagakura	(KKR Sapporo Medical Center, Department of Radiology, JP)
	Kazunari Abe	(Honamino -sato Clinic, Department of Rehabilitation Sciences, JP)
	Shinobu Uto	(Keio University Hospital Department of Nursing, JP)
	Teruhisa Azuma	(Nara Prefecture General Medical Center, Division of General Internal Medicine, JP)

Session Information

Chair	Tomonobu Koizumi	(Nagano Prefectural Kiso Hospital, JP)
	Junya Sato	(Shonan University of Medical Science, JP)
Keynote Lecture
	Koji Matsumoto	(Hyogo Cancer Center Division of Medical Oncology/ Research, JP)
Speaker	Yasunari Okuda	(Jichi Medical University Hospital Department of Pharmacy, JP)
	Youta Yatagai	(Tochigi　Cancer　Center, JP)
	Hideki Yanome	(Department of Nutrition, Aizawa Hospital, Jisenkai Social Medical Foundation, JP)
	Toshiki Nakamura	(Akebono Pharmacy Group, Akebono Pharmacy, JP)
	Hisanori Shimizu	(Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital, JP)

Symposium
Optimization of long-term health management of childhood and adolescent cancer survivors:how can we support their transition to adult care?

Session Information

Although the importance of long-term follow-up and transitional support for late complications in survivors who experienced cancer treatment during childhood and adolescence is being recognized, sufficient system development is not yet in place.
This project aims to discuss the long-term health management of survivors, incorporating perspectives from the individuals themselves and their family doctors. We will report on the current status and challenges in medical aspects while discussing future directions.

Chair	Chikako Shimizu	(Department of Breast and Medical Oncology, National Center for Global Health and Medicine, JP)
	Hatoe Skaamoto	(National Cancer Center Hospital East, JP)
Speaker	Daisuke Masumoto	(Childhood Cancer Survivors Network in Japan, JP)
	Kimikazu Matsumoto	(Children’s Cancer Center, National Center for Child Health and Development, JP)
	Tomoko Taniyama	(National Center for Global Health and Medicine, Comprehensive Cancer Center, JP)
	Satoshi Kanke	(Department of General Internal Medicine and Family Medicine, JP)
Special Remarks
	Yuka Kato	(Shizuoka Children Hospital Department of Nursing, JP)
Commentator
	Bradley J. Zebrack	(University of Michigan Rogel Cancer Center and School of Social Work, USA)

Clinical Trial Facilitation Program

Symposium
Current updates to learn about clinical trial modernization

Session Information

The costs—both in terms of human resources, time, and finances—associated with the development of new treatments have been increasing yearly. As a result, efforts to optimize and streamline clinical trials with the aim of cost reduction have been gaining momentum. In the field of cancer treatment development, new evaluation metrics, such as differences in restricted mean survival time (RMST) in situations where survival curves diverge later (reflecting delayed survival benefits), along with the utilization of real-world data, adaptive designs, and Bayesian designs, are prime examples of such efforts. This symposium will discuss the latest domestic and international trends in these new frameworks for clinical trials.

Chair	Hideharu Yamamoto	(Chugai Pharmaceutical Co., Ltd., JP)
	Kenichi Nakamura	(Department of International Clinical Development, National Cancer Center Hospital, JP)
Speaker	Hajime Uno	(Dana-Farber Cancer Institute / Harvard Medical School, USA)
	Shogo Nomura	(Graduate School of Medicine, The University of Tokyo, JP)
	Martin Posch	(Medical University of Vienna, AUT)
	Hideki Suganami	(Japan Pharmaceutical Manufacturers Association, JP)

Session Information

Chair	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital, JP)
	Shogo Nomura	(Graduate School of Medicine, The University of Tokyo, JP)
Speaker	Takayuki Yoshino	(National Cancer Center Hospital East, JP)
	Hideaki Bando	(Department of Gastrointestinal Oncology, JP)
	Akinari Tsukada	(Pharmaceuticals and Medical Devices Agency Office of New Drug Ⅴ, JP)
	Hidehito Horinouchi	(Department of Thoracic Oncology, National Cancer Center Hospital, JP)

Symposium
Challenges for implementation of translational research in clinical trials

Session Information

Translational Research (TR) is an approach that swiftly applies findings from basic research to the clinical forefront, serving as a key to enhancing the quality of patient care. Recently, TR methodologies have seen remarkable advancements, contributing to the development of more effective treatment strategies at various stages of clinical trials. However, when it comes to essential requirements for promoting TR, such as specimen collection in clinical trials and the introduction of novel technologies, Japan is notably lagging behind other countries. This symposium aims to invite domestic experts and leading figures in international TR research to explore challenges and opportunities for the development and implementation of new therapeutic methods and TR.

Chair	Yoshiaki Nakamura	(National Cancer Center Hospital East, JP)
	Yu Sunakawa	(Department of Clinical Oncology, St. Marianna University School of Medicine, JP)
Speaker	Hiromichi Ebi	(Precision Medicine Center, Aichi Cancer Center, JP)
	Takafumi Koyama	(Department of Experimental Therapuetics, JP)
	Akihito Kawazoe	(NCCE, JP)
	Chigusa Morizane	(Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, JP)
	Woong-Yang Park	(GxD Inc., KOR)

Patient Advocacy/Survivorship

Session Information

Chair	Kiyotaka Watanabe	(Division of Medical Oncology, Department of Medicine, School of Medicine, Teikyo University, JP)
	Yukari Tsubata	(Shimane University, JP)
Keynote Lecture
	Etsuko Aruga	(Teikyo University School of Medicine, Department of Palliative Medicine, JP)
	Naomi Sakurai	(CSR Project, JP)
Panelist	Maiko Higuchi	(Toyama University hospital Nursing, JP)
	Kayoko Katayama	(Faculty of Informatics, Gunma University, JP)
	Jiichiro Sasaki	(Division of Clinical Oncology, Department of Comprehensive Medicine, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, JP)

Joint Symposium with International Societies

ASCO/JSMO

Session Information

In this session, we aim to share information on the latest advancements in cancer treatment development, including new drugs in early-line therapy and emerging biomarker research.

Chair	Lynn Schuchter	(ASCO - Chair of Board, University of Pennsylvania - Director, Tara Miller Melanoma Center, USA)
	Hironobu Minami	(Kobe University Graduate School of Medicine, Medical Oncology/Hematology, JP)
Speaker	Erika P. Hamilton	(Sarah Cannon Research Institute, USA)
	Anna Spreafico	(Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, CAN)
	Bando Hideaki	(Division of Drug and Diagnostic Development Promotion, National Cancer Center Hospital East, JP)
	Takafumi Koyama	(Department of Experimental Therapeutics, JP)

ESMO/JSMO

Session Information

Cancer care is a field with many topics that require discussion, including the timing of CGP, subsequent treatment strategies, and the growing research on whole Genome sequencing, which is also being advanced in Japan. We believe that discussing the situation in Europe would provide valuable insights.

Chair	Kan Yonemori	(National Cacer Center Hosptial, Japan, JP)
Speaker	Raffaela Casolino	(World Health Organization, CHE)
	Isabell Durant Zaleski	(Assistance Publique Hôpitaux de Paris, FRA)
	Kuniko Sunami	(Department of Laboratory Medicine, National Cancer Center Hospital, JP)
	Katsutoshi Oda	(Div. of Integrative Genomics, The University of Tokyo, JP)

Asian Pacific Society/JSMO

Session Information

The promotion of international cooperation to lead to the development of region-specific cancer treatment and prevention methods.

Chair	Kazuki Sudo	(National Cancer Center, Department of Medical Oncology, JP)
	Ravindran Kanesvaran	(National Cancer Centre Singapore, SGP)
Speaker	Do-Youn Oh	(Seoul National University Hospital, KOR)
	Janice Tsang	(Hong Kong Breast Oncology Group (HKBOG), HKG)
	Takahiro Kogawa	(Cancer Institute Hospital of JFCR, Dept of Advanced Medical Development, JP)
	Kadowaki Shigenori	(Department of Clinical Oncology, Aichi Cancer Center Hospital, JP)

SIOG/JSMO

SIOG/JSMO Joint Symposium
Lessons to Learn from the Leading Nations in Geriatric Oncology

Session Information

Given the feedback from participants in previous symposiums, there has been a strong interest in understanding the clinical practices and research in countries leading the field of geriatric oncology, such as France and Belgium. Therefore, we will invite speakers from France and Belgium to present the latest advancements and innovations in geriatric oncology. Alongside these presentations, we aim to clarify what Japan is doing well, where it may be lacking, and discuss the direction in which Japanese geriatric oncology should advance.

Chair	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine, JP)
	Hiroshi Yamamoto	(Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology, JP)
Speaker	Hiroshi Yamamoto	(Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology, JP)
	Rabia Boulahssass	(teaching hospital of nice, FRA)
	Hans Wildiers	(University Hospitals Leuven, BEL)
	Ken Sugimoto	(General Geriatric Medicine, Kawasaki Medical School, JP)

Joint Symposium with Japanese Societies

Japanese Cancer Association (JCA)/Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Takashi Kohno	(C-CAT, National Cancer Center, JP)
	Manabu Muto	(Department of Medical Oncology, Kyoto University Graduate School of Medicine, JP)
	Seiji Yano	(Department of Respiratory Medicine, Kanazawa University, JP)
Speaker	Seishi Ogawa	(Department of Pathology and Tumor Biology, Kyoto University, JP)
	Hiroyoshi Nishikawa	(Division of Cancer Immunology, Research Institute / EPOC, National Cancer Center, Department of Immunology, Nagoya University Graduate School of Medicine, JP)
	Masaaki Ito	(Department of Colorectal Surgery, National Cancer Center Hospital East, JP)
	Satoshi Nishizuka	(Devision of Biomedical Research and Development, Iwate Medical University Institute for Biomedical Sciences, JP)
	Yozo Nakazawa	(Department of Pediatrics, Shinshu University School of Medicine, JP)
	Tetauji Naka	(Divition of Allergy and Rheumatology School of Medcine Iwate Medical School, JP)

Japanese Society for Radiation Oncology (JASTRO)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Hitoshi Ikushima	(Department of Therapeutic Radiology, Tokushima University Graduate School, JP)
	Sadamoto Zenda	(Department of Radiation Oncology, National Cancer Center Hospital East, JP)
Speaker	Katsuyuki Shirai	(Department of Radiation Oncology, Jichi Medical University Hospital, JP)
	Yasuo Matsumoto	(Niigata Cancer Center Hospital, JP)
	Kei Ito	(Tokyo Metropolitan Komagome Hospital, Department of Radiation Oncology, JP)
	Taiji Koyama	(Department of Oncology and Hematology, Kobe University Hospital, JP)

Japanese Society of Cancer Nursing (JSCN)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Kaori Yagasaki	(Faculty of Nursing and Medical Care, Keio University, JP)
	Koji Matsumoto	(Hyogo Cancer Center, Division of Medical Oncology, JP)
Keynote Lecture
	Tomonori Mizutani	(Department of Medical Oncology, Kyorin University Faculty of Medicine, JP)
Speaker	Kohei Arimizu	(Geriatric Oncology Service, the Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center, JP)
	Sawa Fujita	(University of Kochi Faculty of Nursing, JP)
	Risako Unoki	(Yokohama Municipal Citizen’s Hospital, Nursing Department, JP)

Japanese Society for Palliative Medicine (JSPM)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Eriko Satomi	(Department of Palliative Medicine, National Cancer Center Hospital, JP)
	Harue Arao	(Osaka University Graduate School of Medicine, JP)
Speaker	Maiko Fujimori	(National Cancer Center Institute for Cancer Control, JP)
	Tatsuo Akechi	(Nagoya City University Graduate School of Medical Sciences, JP)
	Yuki Kojima	(Department of Medical Oncology, National Cancer Center Hospital, JP)
	Masanori Mori	(Division of Palliative and Supportive Care, Seirei Mikatahara General Hospital, JP)
	Kazuyuki Niki	(Osaka University Graduate School and School of Pharmaceutical Sciences, JP)

Japan Society of Human Genetics (JSHG)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Issei Imoto	(Aichi Cancer Center Research Institute, JP)
	Katsuya Tsuchihara	(EPOC, National Cancer Center Japan, JP)
Speaker	Akira Chiba	(Cancer and Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare, JP)
	Akira Hirasawa	(Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, JP)
	Takeshi Kuwata	(Department of Genetic Medicine and Services, JP)
	Motohiro Kato	(Department of Pediatrics, the University of Tokyo, JP)
	Izumi Okawara	(Japanese NF1 patient group named as To Smile, JP)

Japanese Circulation Society (JCS)/Japanese Onco-Cardiology Society (JOCS)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Yuko Tanabe	(Toranomon Hospital, JP)
	Yoshihiro Fukumoto	(Cardiovascular Medicine, Kurume University School of Medicine, JP)
Speaker	Mikio Mukai	(Osaka Center for Cancer and Cardiovascular Disease Prevention, JP)
	Yoichi Naito	(Department of General Internal Medicine, National Cancer Center Hospital East, JP)
	Kazuhiro Bandai	(Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, JP)
	Yoshihiro Tanaka	(Department of Gastroenterological surgery/ Pediatric surgery, Gifu University, Graduate School of Medicine, JP)
	Tatsuhiro Shibata	(Department of Internal Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, JP)
	Yoshihisa Nakagawa	(Shiga University of Medical Science, Department of Cardiovascular Medicine, JP)

Japanese Society of Hematolog (JSH)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Takanori Teshima	(Hematology, Hokkaido University, JP)
	Dai Maruyama	(Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, JP)
Speaker	Koji Tamada	(Department of Immunology, Yamaguchi University Graduate School of Medicine/Director, Research Institute for Cell Design Medical Science, Yamaguchi University, JP)
	Yoshiyuki Takahashi	(Nagoya University Graduate School of Medicine Department of Pediatrics, JP)
	Miki Ando	(Department of Hematology, Juntendo University School of Medicine, JP)
	Shigehisa Kitano	(Department of Advanced Medical Development, The Cancer Institute Hospital of JFCR, JP)
	Koji Izutsu	(Department of Hematology, National Cancer Center Hospital, JP)

Japanese Orthopaedic Association (JOA)/Japanese Society of Medical Oncology (JSMO)

Session Information

Chair	Akira Kawai	(Department of Musculoskeletal Oncology and Rehabilitation Medicine, JP)
	Hiroyuki Shibata	(Dept Clinical Oncology, Graduate School of Medicine, Akita University, JP)
Speaker	Hirotaka Kawano	(Department of Orthopaedic Surgery Teikyo University School of Medicine, JP)
	Teruhisa Azuma	(Nara Prefecture General Medical Center, Department of General Internal Medicine, JP)
	Shigemi Matsumoto	(Dwpartment of Real World Data R & D, Graduate School of Medicine, Kyoto University, JP)
	Eiji Nakata	(Department of orthopaedic surgery, Okayama University, JP)
	Yasunori Arai	(Department of Diagnostic Radilogy, National Cancer Center Hospital East, JP)
	Kei Ito	(Tokyo Metropolitan Komagome Hospital, Department of Radiation Oncology, JP)
	Eisuke Kobayashi	(Department of Muscloskeletal Oncology, National Cancer Center Hospital, JP)
	Hideo Morioka	(Department of Orthopaedic Surgery, National Hospital Organization Tokyo Medical Center, JP)

Educational Lecture